AlphAIalphai — Financial news for AI agents
SEC EDGARAUG 122 min read$AMPH

PRINS RICHARD K sold $162K of AMPH

PRINS RICHARD K sold 7,973 shares of Amphastar Pharmaceuticals, Inc. (AMPH) at $20.30 ($0.16M total) on 2026-08-11.

Original reporting
SEC EDGAR · PRINS RICHARD K
Published Aug 12, 2026, 10:14 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 12, 2026, 10:20 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$AMPH
Neutral
medium confidence
Mentioned
$AMPH
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$AMPHNeutralLow
01

Why it matters

The disclosure updates insider activity records but does not provide new information about Amphastar’s business, guidance, or regulatory status.

02

Market read

Traders may monitor for follow-on insider activity, but this specific sale is unlikely to drive a material repricing without additional company news.

03

What to watch

No 10b5-1 plan is indicated, so traders may scrutinize timing, but the article provides no reason for the sale or any accompanying company-specific negative catalyst.

Relevance 4/10Novelty 3/10Timing: filed 2026-08-12 after-hours; sale dated 2026-08-11

Background

The article is an SEC Form 4 insider transaction disclosure for Amphastar Pharmaceuticals, Inc.

Company-level read

Ticker impact

$AMPHNeutralMedium confidence
Context

Amphastar director Richard K Prins filed a Form 4 selling 7,973 shares at $20.30 on 2026-08-11, totaling about $161.9K.

Expected impact

Likely limited near-term impact; treat as low-signal unless repeated or paired with other company-specific news.

Evidence & confidence

The filing is primary-source and time-stamped, but the disclosed transaction size is modest and does not include a stated company catalyst or new operational/regulatory development.

Market effects

Sector

No clear sector read-through from a single director’s modest insider sale.

Regional

None.

Global

None.

Counterpoint

What could challenge this read

If the director’s sales are part of a broader, repeated pattern, it could reflect liquidity needs rather than bearish fundamentals, reducing the need to overreact.

Key entities

  • issuer
    Amphastar Pharmaceuticals, Inc.

    Subject of the Form 4 insider sale by a director.

  • insider
    PRINS RICHARD K

    Director who sold 7,973 shares at $20.30 on 2026-08-11.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

AMPH insider trading history →

Related articles

AUG 14
$AMPHMedAI 8/10

Amphastar (AMPH) Q2 2026 Earnings Call Transcript

Amphastar (AMPH) reported Q2 2026 net revenues of $183.9 million, up 5% from $174.4 million, and gross margin of 50.8% versus 49.6%. GAAP net income was $30.3 million ($0.67/share). Adjusted non-GAAP net income was $40.8 million ($0.91/share). IMS remediation tied to an FDA warning letter is expected to add $2 million to $3 million per quarter, while full-year sales growth guidance remains mid-single digit to high single digit.

fool.com6 min
AUG 6
$AMPHMedAI 8/10

Amphastar Pharmaceuticals (NASDAQ:AMPH) Posts Better

Amphastar Pharmaceuticals (NASDAQ:AMPH) reported Q2 2026 results with revenue up 5.4% year on year to $183.9 million, exceeding Wall Street estimates by 2%, according to the company. Non-GAAP adjusted EPS was $0.91, up from $0.85, and 48.3% above consensus. The stock rose 4.5% to $20.70 after the release.

financialcontent.com4 min
AUG 6
$AMPHMed

Amphastar Pharmaceuticals, Inc. (AMPH): Results of Operations and Financial Condition

Amphastar Pharmaceuticals, Inc. (AMPH) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 amph-20260806xex99d1.htm EX-99.1 EXHIBIT 99.1 ​ Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2026 ​ - Net revenues of $183.9 million for the three months ended June 30, 2026 ​ - GAAP net income of $30.3 million, or $0.67 per sh

SEC EDGAR 8-K7 min
JUL 9
$AMPHMedAI 8/10

A New Over-the-Counter Naloxone Nasal Spray Is Now Available at Pharmacies

The FDA approved Rextovy, a 4 mg naloxone hydrochloride nasal spray by Amphastar Pharmaceuticals, for over-the-counter sale on June 16, 2026. It joins Narcan (Emergent BioSolutions) and RiVive (Harm Reduction Therapeutics) as OTC naloxone options. The article cites overdose-death figures and says expanded access may affect retail pricing and availability.

medicaldaily.com5 min
JUN 10
$AMPHMed

Amphastar Pharmaceuticals Pivots to Proprietary Drugs, Biosimilars for Growth

Amphastar Pharmaceuticals said it is leaning more on proprietary drugs and biosimilars to drive growth, while keeping BAQSIMI and Primatene MIST as key branded products. In Phase 1, AMP-101 (intranasal epinephrine) and other early programs include AMP-105/109 oncology and AMP-107 for wet AMD. The company forecasts BAQSIMI peak sales of $250–$275M and peak incremental adjusted EPS of $2–$2.50, and Primatene MIST sales of $109M last year with high-single-digit growth. Amphastar reported $285M cash

finance.yahoo.com7 min
JUN 2
$AMPHMedAI 8/10

Amphastar Pharmaceuticals, Inc. (AMPH) Price Target Cut to $21 At Piper Sandler Amid Pipeline Uncertainty

Piper Sandler cut its price target for Amphastar Pharmaceuticals (NASDAQ: AMPH) from $25 to $21 while keeping a Neutral rating, TheFly reported May 11. The firm cited limited visibility on when pipeline programs will produce meaningful results. Amphastar’s May 7 Q1 ended March 31, 2026 net revenues were $171.2M; GAAP EPS $0.14 and adjusted EPS $0.42.

finance.yahoo.com4 min